Cleavage of membrane-associated proteins with the release of biologically active macromolecules is an emerging theme in biology. However, little is known about the nature and regulation of the involved proteases or about the physiological inducers of the shedding process. We here report that rapid and massive shedding of the interleukin 6 receptor (IL-6R) and the lipopolysaccharide receptor (CD14) occurs from primary and transfected cells attacked by two prototypes of pore-forming bacterial toxins, streptolysin 0 and Escherichia coli hemolysin. Shedding is not induced by an streptolysin 0 toxin mutant which retains cell binding capacity but lacks pore-forming activity. The toxin-dependent cleavage site of the IL-6R was mapped to a position close to, but distinct from, that observed after stimulation with phorbol myristate acetate. Soluble IL-6R that was shed from toxin-treated cells bound its ligand and induced an IL-6-specific signal in cells that primarily lacked the IL-6R. Transsignaling by soluble IL-6R and soluble CD14 is known to dramatically broaden the spectrum of host cells for IL-6 and lipopolysaccharide, and is thus an important mechanism underlying their systemic inflammatory effects. Our findings uncover a novel mechanism that can help to explain the long-range detrimental action of pore-forming toxins in the host organism.
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Many membrane-associated, biologically important molecules can be released from cells by a proteolytic cleavage process called shedding. These include cytokines, receptors for cytokines and growth factors, and cellular adhesion proteins (1, 2) . Soluble receptors for cytokines and growth factors retain their ligand-binding capacity and this can have different consequences. First, soluble receptors may act as competitive inhibitors of the cognate ligands. The soluble receptors for interleukin 1 (IL-1) and tumor necrosis factor (TNF) have been shown to inhibit IL-1 and TNF-specific responses (reviewed in ref. 2) . Second, ligands bound to their soluble receptors may exhibit prolonged plasma half lives and thereby act as a depot for the free ligand. Such a biological activity has recently been ascribed to IL-4 (reviewed in ref. 2) . Third, soluble cytokine receptors may also act as agonists (2) . For example, soluble IL-6 receptor (sIL-6R) and soluble ciliary neurotrophic factor receptor bind by specific interactions to receptorless bystander cells, rendering the latter sensitive to the action of the respective cytokines (2, 3) . An analogous phenomenon has been documented for the soluble lipopolysaccharide (LPS) receptor (sCD14), which binds to bystander cells and renders these susceptible to stimulation with LPS (4, 5) .
Relatively little is known on the nature of the shedding proteases or their physiological inducers. One pathway for activation of these proteases involves activation of protein kinase C (PKC), since exposure of cells to phorbol ester causes shedding of many membrane proteins like TNF-a, the p60 TNF receptor, transforming growth factor a (TGF-a), and IL-6R from cells of monocytic, liver, or kidney origin (1, 2, (6) (7) (8) (9) . Shedding can, however, also be induced via two PKCindependent pathways, one of which is Ca2+ dependent (1). The membrane-bound shedding protease (or family of related proteases) has been characterized as a metalloproteinase that is inhibitable by the hydroxamic acid compound TAPI (TNF-a protease inhibitor), and to a lesser degree by conventional metalloproteinase inhibitors such as 1,10-phenanthroline (1, 8, 9) . The specificity of the shedding protease has been studied by changing the cleavage site of several substrates including TNF-a, TGF-a, TNF-R, and IL-6R (1, 2, 10, 11). These studies indicated that there is no strict sequence specificity; deletion of a given cleavage site, however, led to complete abolishment of shedding of the respective protein (1, 2) .
Investigations into the mechanisms by which endotoxin (LPS) and superantigens induce cytokine-overload reactions in the infected organism are legion. In contrast, the pathophysiological implications of cell damage provoked by proteinaceous cytotoxins have received relatively little attention. In the course of our studies on pore-forming bacterial proteins, we have found that these widespread toxins are endowed with a capacity to provoke a surprisingly wide spectrum of shortand long-range pathological reactions including the activation of PKC via a G-protein dependent pathway (12, 13) .
In this study, we show that two prototypes of pore-forming toxins, streptolysin 0 (SLO) and Escherichia coli hemolysin (HlyA), induce rapid and massive shedding of CD14 and IL-6R, and that the cleaved sIL-6R is biologically active in transsignaling. The results uncover a novel mechanism by which pore-forming toxins can promote inflammatory pro- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
from ICN. DMEM with glutamax, MEM, and penicillin/ streptomycin were from GIBCO. FCS was from Seromed (Berlin). The novel metalloproteinase inhibitor TAPI (N-{D,L-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl}L-3-(2'naphthyl)-alanyl-L-alanine,2-amino-ethylamide) was prepared at Immunex (8) . The preparation of the polyclonal monospecific antiserum against IL-6R has been described (14) . The generation of the expression vector pCDM8-huIL-6R and pCDM8-huIL-6R AAB which lacks the PMA-induced cleavage site was described (11) . Soluble human IL-6R was expressed as described (15) . SLO and HlyA were purified as described (16, 17) . Granulocyte/macrophage colony-stimulating factor and interferon-y were from Essex Pharma (Munich) and Bioferon (Laupheim, Germany), respectively.
Monocyte Isolation and Treatment. Monocytes were isolated from citrated buffy coats, which were kindly provided by the Blood Transfusion Center of the University of Mainz. Monocytes were isolated as described (18) . Monocyte cell suspensions regularly contained 70-90% monocytes as determined by flow cytometry. They were adjusted with MEM to densities of 1.5 x 106 cells/ml, and 1 ml aliquots of cell suspensions were applied per well to 24-well cell culture plates (Nunc). After 1 h incubation of cells at 37°C/5% C02, the plates were washed twice with Hanks' balanced salt solution. Experiments were performed both with freshly isolated monocytes and with macrophages, which were obtained by culturing the cells in MEM supplemented with 10% human serum from blood group AB donors and 2.5 ng of granulocyte/ macrophage colony-stimulating factor per ml and 0.5 ng of interferon-y per ml for 5 days. The cells were treated with HlyA (0.01-10 ,g/ml) or SLO (1-5 ,ug/ml). At the times given in the figure legends, the medium was then removed and centrifuged for 5 min at 13,000 X g.
Quantification of sIL-6R and sCD-14. Quantification of sIL-6R and sCD14 in cell supernatants was undertaken following the instructions supplied by the manufacturers of the ELISA kits. The sIL-6R ELISA was supplied by Laboserv Diagnostica (Giessen, Germany). The sCD14 ELISA was obtained from Medgenix Diagnostics (Ratingen, Germany).
Quantification of cellular IL-6R and CD14 was undertaken by solubilizing the cells in 20 mM Nonidet P-40 in the presence of a commercial protease inhibitor cocktail (Complete; Boehringer Mannheim) and analysis of the detergent extracts by ELISA.
Cell Culture and Transient Transfection of COS-7 Cells.
COS-7 cells and HepG2-IL-6 cells (15) 12 .5% SDS/polyacrylamide gels. After intensifying fluorography with sodium salicylate, the gels were dried and exposed to x-ray film.
Northern Blot Analysis. RNA was prepared by using RNeasy (Quiagen, Hilden, Germany). Northern blotting was carried out as described (19) . Nylon membranes (GeneScreenPlus; NEN) were hybridized with a 0.9 kb Hinfl fragment of haptoglobin cDNA labeled by random priming (20) .
RESULTS
PMA, SLO, and HlyA Induce Shedding of the IL-6R. As shown in Fig. 1A , treatment of human macrophages for 60 min with PMA, SLO, and HlyA led to the release of sIL-6R. To approximate the extent of shedding, detergent extracts of cells were applied to the ELISA. As shown in Fig. 1B , the relative cellular content of IL-6R was reduced by -35% and 50% after PMA and HlyA treatment, respectively. Similar results for HlyA were obtained with monocytes, but PMA-induced shedding in these cells was usually lower than in macrophages. The induction of shedding by HlyA ( Fig. 2A) and SLO (data not shown) was dose-dependent; 0.3 unit of HlyA per ml (corresponding to 30 ng/ml) led to half maximal release of sIL-6R.
Shedding of the IL-6R from macrophages was rapid and almost complete after 10 min. Shedding thus displayed more rapid kinetics than observed with PMA, where shedding and Asp-358 close to the putative transmembrane domain (11) . As expected, cells transfected with the mutant IL-6R AA,B lacking 10 amino acid residues around this cleavage site showed no shedding after stimulation with PMA (Fig. 5) . However, when the same cells were treated with SLO or HlyA, shedding occurred to a comparable extent as with the unaltered IL-6R (Fig. 5) .
According to the ELISA measurements, 30-50% of the cell-associated IL-6R was released as a soluble protein, whereas the pulse-chase experiments showed 50-100% shedding of the IL-6R. It should be considered that the ELISA procedure measures total IL-6R in the cell lysate and supernatant, whereas immunoprecipitation after pulse-chase labeling only follows the fate of the IL-6R synthesized during the pulse period. This difference probably accounts for the apparent discrepancy between the results of ELISA measurements and immunoprecipitation.
In any event, our data demonstrate that toxin-induced cleavage of the IL-6R is a posttranslational event, and that cleavage occurs at a shedding site distinct from that identified following phorbol ester stimulation.
Released sIL-6R Is Biologically Active. To test whether the sIL-6R released by the cells treated with PMA, SLO, or HlyA was biologically active, we employed the cell line HepG2-IL-6 which does not express the IL-6R at the cell surface (15) . These human hepatoma cells secrete large amounts of human IL-6, and induction of acute phase proteins like haptoglobin or a, antichymotrypsin is solely dependent on the presence of soluble human IL-6R (15) . As shown in Fig. 6 (4) . As shown in Fig. 7A , treatment of human monocytes with SLO or HlyA also led to release of sCD14. As in the case of IL-6R, the toxin-induced shedding of CD14 was not affected by the addition of staurosporin, but could be completely inhibited by the addition of TAPI (Fig. 7B) . With regard to other protease inhibitors, the same results were obtained as described above for IL-6R. Analysis of cell extracts indicated a reduction in CD14 content of -30% following toxin-induced shedding (Fig. 7C) .
Although CD14 is a glycosylphosphadidylinositol-anchored protein, it has been established that the soluble form of CD14 is generated by proteolysis (4). Our observation that the inhibitor of metalloproteinase TAPI completely inhibited shedding of CD14 was entirely in line with this finding. From the presented data it appears that SLO and HlyA trigger cleavage of CD14 and IL-6R by similar or identical mechanisms.
Shedding of IL-6R and CD14 Is Dependent on PoreForming Activity of SLO. It was of interest to determine whether shedding of IL-6R and CD14 was dependent on the pore-forming activity of SLO. A mutant toxin containing a single amino acid substitution has been constructed that fully retains cell-binding activity but lacks pore-forming activity due to faulty polymerization (M.P. and S.B., unpublished data). It was found that the mutant SLO toxin applied at concentrations up to 50 ,ug/ml entirely failed to induce shedding of IL-6R or CD14. Hence, shedding was dependent on the pore-forming function (data not shown).
DISCUSSION
Mechanism of Shedding Induced by Bacterial Cytolysins. As is the cahe with other shedding stimuli, the mechanisms underlying the cleavage of IL-6R and CD14 induced by pore-forming toxins await elucidation. Toxin-induced shedding displayed a number of characteristic features. First, it was not inhibitable by staurosporin and hence did not involve PKC. Second, as shown with the bindable but noncytotoxic SLO mutant, shedding was dependent on transmembrane pore formation and was Ca2+-independent. The kinetics of shedding were more rapid than those observed with other stimuli, and they closely followed the kinetics of pore formation. Third, the cleavage site used for shedding of the IL-6R after stimulation with PMA was obviously different from the one used after stimulation with PMA, because an IL-6R mutant lacking the PMA-dependent cleavage site was still shed from toxintreated cells. The monospecific antibody employed for immunoprecipitation of the IL-6R recognizes an epitope 21 amino acids upstream of the PMA specific cleavage site (14) . Interestingly, shedding of the IL-6R is not prevented by this antibody (J. Mullberg and S.R.-J., unpublished data). The sIL-6R released after treatment with SLO or HlyA was recognized by this antibody, so the alternative cleavage site must lie within the stretch of 21 amino acid residues. Since the IL-6R AA,B mutant, which lacks 5 amino acids upstream of the cleavage site (Fig. 5) 
